12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Roche sales and marketing update

Roche launched Perjeta pertuzumab in the U.K. to treat previously untreated HER2-positive metastatic breast cancer. The European Commission approved the product earlier this...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >